Royalty Pharma plc Overview
Valuation check: RPRX's P/E ratio is 24.32, below the Healthcare sector average of 24.78.
Get informed when a big investor buys or sells
+ Follow24.32
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, RPRX shows a P/E ratio of 24.32. That is below the Healthcare sector average of 24.78. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 24.78. Royalty Pharma plc is at 24.32, which is lower that average. That is roughly 1.9% below the sector mean. Use the comparison chart on this page to see how RPRX stacks up against individual peers as well.
Investors watch RPRX's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Royalty Pharma plc's latest reading is 24.32. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Royalty Pharma plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently 24.32) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 24.78, while RPRX is at 24.32. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
